natgillin/translations-raw huggingface dataset:
The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥70 points from baseline at the 4-week evaluation and without an increase in the use of medicinal products or surgery for Crohn’s disease.
Primarnu mjeru ishoda ispitivanja činio je udio bolesnika koji su pokazali klinički odgovor, definiran kao smanjenje CDAI za ≥ 70 bodova u odnosu na početne vrijednosti nakon 4 tjedna, bez povećanja doza lijekova koji se daju u Crohnovoj bolesti ili kirurškog liječenja Crohnove bolesti.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥ 50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn’s disease.
Primarna mjera ishoda bila je udio bolesnika koji su pokazali klinički odgovor, definiran kao ≥ 50%-tno smanjenje početnog broja fistula koje su se cijedile na lagani pritisak u najmanje dva uzastopna dolaska (u razmaku od 4 tjedna), bez povećanja doze lijekova za Crohnovu bolest ili kirurškog liječenja Crohnove bolesti.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥ 50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn’s disease.
Primarna mjera ishoda bila je udio bolesnika koji su pokazali klinički odgovor, definiran kao ≥ 50%-tno smanjenje početnog broja fistula koje su se cijedile na lagani pritisak u najmanje dvije uzastopne posjete (u razmaku od 4 tjedna), bez povećanja doze lijekova za Crohnovu bolest ili kirurškog liječenja Crohnove bolesti.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn’s disease.
Primarna mjera ishoda bila je udio bolesnika koji su pokazali klinički odgovor, definiran kao ≥ 50%-tno smanjenje početnog broja fistula koje su se cijedile na lagani pritisak u najmanje dvije uzastopne posjete (u razmaku od 4 tjedna), bez povećanja doze lijekova za Crohnovu bolest ili kirurškog liječenja Crohnove bolesti.
The primary endpoint was the responder rate in walking speed as measured by the Timed 25-foot Walk (T25FW).
Primarni ishod je bio stopa bolesnika s odgovorom u poboljšanju brzine hodanja, mjerene testom vremenski ograničenog hodanja (T25FW).
The primary endpoint was the response rate at month 3 defined as the proportion of patients with at least 60% improvement in the mEASI (modified Eczema Area and Severity Index) between baseline and month 3.
Primarni ishod bila je stopa odgovora nakon 3 mjeseca definirana kao udio bolesnika s najmanje 60% poboljšanja na modificiranom indeksu površine i težine ekcema (mEASI; engl. modified Eczema Area and Severity Index) do 3. mjeseca u odnosu na početno stanje.
The primary endpoint was the time to first occurrence of a clinical failure event, defined as:
Primarna mjera ishoda bilo je vrijeme do prvog nastupa događaja kliničkog neuspjeha, koji se definirao kao:
The primary endpoint was the time to first occurrence of a morbidity or mortality event, up to the end of double-blind treatment, defined as death, or atrial septostomy, or lung transplantation, or initiation of intravenous (i.v.) or subcutaneous (s.c.) prostanoids, or other worsening of PAH.
Primarni ishod bilo je vrijeme do prve pojave događaja morbiditeta ili mortaliteta pa sve do kraja dvostruko slijepog liječenja, definiranog kao smrt ili atrijska septostomija ili transplantacija pluća ili početak primjene intravenskih (i.v.) ili supkutanih (s.c.) prostanoida ili druge vrste pogoršanja PAH-a.
The primary endpoint, the composite of the occurrence or time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina, was non-significantly lower for linagliptin versus combined active and placebo comparators [Hazard ratio 0.78 (95% confidence interval 0.55;1.12)].
Primarna mjera ishoda, koja uključuje pojavu ili vremena do prve pojave KV-smrti, nefatalnog infarkta miokarda, nefatalnog moždanog udara ili hospitalizacije zbog nestabilne angine pektoris, bila je neznačajno niža za linagliptin u odnosu na kombinirane aktivne i placebo-komparatore [omjer hazarda 0,78 (95% interval pouzdanosti 0,55;1,12)].
The primary endpoint, the composite of: the occurrence or time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina, was non-significantly lower for linagliptin versus combined active and placebo comparators [Hazard ratio 0.78 (95% confidence interval 0.55;1.12)].
Primarna mjera ishoda, kompozitna mjera sastavljena od: pojave ili vremena do prve pojave KV-smrti, nefatalnog infarkta miokarda, nefatalnog moždanog udara ili hospitalizacije zbog nestabilne angine pektoris, bila je neznačajno niža za linagliptin u odnosu na kombinirane aktivne i placebo-komparatore [omjer hazarda 0,78 (95% interval pouzdanosti 0,55;1,12)].
The primary endpoints of this study, progression-free survival (PFS), as assessed by hazard ratio, and overall response rate (ORR) were determined based on assessments made by a blinded Independent Review Committee.
Primarne mjere ishoda u ovom ispitivanju – preživljenje bez progresije bolesti (engl. progression-free survival, PFS) ocijenjeno prema omjeru hazarda te stopa ukupnog odgovora (engl. overall response rate, ORR) – određivale su se na temelju ocjena zaslijepljenog Neovisnog ocjenjivačkog povjerenstva(engl.
The primary endpoints were the reduction of signs and symptoms as assessed by the American College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function.
Primarne mjere ishoda bile su smanjenje znakova i simptoma prema kriterijima Američkog reumatološkog društva (American College of Rheumatology, ACR) (ACR20 za ATTRACT, granična vrijednost ACR-N za ASPIRE), sprečavanje strukturnog oštećenja zglobova te poboljšanje funkcionalne sposobnosti.
The primary endpoints were the reduction of signs and symptoms as assessed by the American College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function.
Primarne mjere ishoda bile su smanjenje znakova i simptoma prema kriterijima Američkog reumatološkog društva (American College of Rheumatology, ACR) (ACR20 za ATTRACT, granična vrijednost ACR-N za ASPIRE), sprječavanje strukturnog oštećenja zglobova te poboljšanje funkcionalne sposobnosti.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine.
Primarni bilijarni, fekalni i urinarni metaboliti u štakora i mačaka identificirani su kao konjugati glutationa izvornih spojeva i N-demetiliranih spinosina A i D. Izlučivanje je primarno preko izmeta i manjim dijelom preko urina.
The primary infant series consists of three doses with the first dose given at 2 months of age and with an interval of at least 1 month between doses.
Primarna imunizacija dojenčadi obuhvaća tri doze, pri čemu se prva primjenjuje u dobi od 2 mjeseca, s razmakom od najmanje 1 mjeseca između pojedinih doza.
The primary infant series consists of three doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses.
Primarna imunizacija dojenčadi sastoji se od tri doze, pri čemu se prva doza uobičajeno primjenjuje u dobi od 2 mjeseca s razmakom od najmanje 1 mjesec između pojedinih doza.
The primary measure of efficacy (ASAS 20) was a ≥ 20% improvement in at least 3 of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, BASFI, and inflammation) and absence of deterioration in the remaining domain.
Primarna mjera djelotvornosti (ASAS 20) bila je ≥ 20%-tno poboljšanje u najmanje 3 od 4 parametra procjene ankilozantnog spondilitisa (Assessment in Ankylosing Spondylitis (ASAS)) (opća procjena bolesnika, bol u leđima, BASFI i upala) te odsutnost pogoršanja preostalog parametra.
The primary measure of efficacy (ASAS 20) was a 20% improvement in at least 3 of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, BASFI, and inflammation) and absence of deterioration in the remaining domain.
Primarna mjera djelotvornosti (ASAS 20) bila je  20%-tno poboljšanje kod najmanje 3 od 4 parametra procjene ankilozantnog spondilitisa (Assessment in Ankylosing Spondylitis (ASAS)) (opća procjena bolesnika, bol u leđima, BASFI i upala) te odsutnost pogoršanja preostalog parametra.
The primary measure of efficacy (ASAS 40) was a 40% improvement in at least three of the four ASAS domains and absence of deterioration in the remaining domain.
Primarna mjera djelotvornosti (ASAS 40) bila je 40-postotno poboljšanje u najmanje tri od četiri parametra procjene ASAS i odsutnost pogoršanja preostalog parametra..
The primary measures of efficacy were changes in excessive daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), and the change in the overall severity of the patient’s narcolepsy symptoms as assessed by the investigator using the Clinical Global Impressions of Change (CGI-c) measure.
Primarne mjere djelotvornosti bile su promjene u pretjeranoj dnevnoj pospanosti koje su određivane pomoću Epworthove skale pospanosti (ESS) te promjene u ukupnoj težini simptoma bolesnika s narkolepsijom koje je procijenjivao ispitivač na temelju ljestvice za procjenu kliničkog općeg dojma promjene (CGI-c, engl.
The primary mechanism of action of Zalmoxis relies on its ability to engraft and stimulate immune- reconstitution.
Primarni mehanizam djelovanja Zalmoxisa zasniva se na njegovoj sposobnosti usađivanja i stimuliranja imunološke rekonstitucije.
The primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (glucuronidation, etc), resulting in a range of metabolites with either reduced pharmacological activity or for which the pharmacological activity has not been established.
Primarni metabolički putovi za umeklidinij su oksidativni (hidroksilacija, O-dealkilacija), a nakon njih slijedi konjugacija (glukuronidacija itd.), čime se stvara niz metabolita koji imaju ili smanjenu farmakološku aktivnost ili njihova farmakološka aktivnost još nije utvrđena.
The primary metabolite is N-desethylbrinzolamide followed by the N-desmethoxypropyl and O-desmethyl metabolites as well as an N-propionic acid analog formed by oxidation of the N-propyl side chain of O-desmethyl brinzolamide.
Glavni metabolit je N-desetilbrinzolamid nakon čega slijede N- desmetoksipropil i O-desmetilni metabiliti kao i analog N-propilne kiseline koji nastaje oksidacijom N- propilnog bočnog lanca O-desmetilbrinzolamida.
The primary metabolite resulting from the cleavage of Arg3-Pro4 bond of the N- terminal sequence by thrombin is not active because of the loss of affinity to the catalytic active site of thrombin.
Primarni metabolit, koji proizlazi iz cijepanja veze Arg3-Pro4 na N-terminalnom kraju sekvence trombinom, nije aktivan zbog gubitka afiniteta za katalitički aktivno mjesto na trombinu.
The primary mode of action of the fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription and recombination.
Primarni način djelovanja fluorokinolona uključuje interakcije s enzimima esencijalnim za važne funkcije DNA kao što su replikacija, trankskripcija i rekombinacija.
The primary objective assessed the incidence of Grade 3 and 4 ALT abnormalities (>5x upper limit of normal (ULN) if baseline ALT ≤ ULN; or >3.5x baseline if baseline ALT > ULN) at Week 48.
Primarni cilj bio je procjena incidencije odstupanja ALT-a stupnja 3 i 4 (>5x od gornje granice normale (GGN) ako je početni ALT ≤ GGN; ili >3,5x početna vrijednost ako je početni ALT > GGN) u 48. tjednu.
The primary objective for this study was to evaluate the efficacy of dabrafenib compared to DTIC with respect to progression-free survival (PFS) per investigator assessment.
Primarni cilj ispitivanja bilo je procijeniti djelotvornost dabrafeniba u usporedbi s DTIC-om s obzirom na preživljenje bez progresije bolesti (PFS) prema procjeni ispitivača.
The primary objective in this study was to determine if dabigatran etexilate was non-inferior to warfarin in reducing the occurrence of the composite endpoint stroke and SEE.
Primarni cilj ove studije bio je odrediti je li dabigatraneteksilat neinferioran varfarinu u odnosu na kompozitni ishod - incidencija moždanog udara i/ili SE-a.
The primary objective of the study was to assess the efficacy of 16 weeks of chronic treatment with oral sildenafil in paediatric subjects to improve exercise capacity as measured by the Cardiopulmonary Exercise Test (CPET) in subjects who were developmentally able to perform the test, n = 115).
Primarni cilj ispitivanja bio je procijeniti djelotvornost 16-tjednog kroničnog peroralnog liječenja sildenafilom u pedijatrijskih ispitanika na poboljšanje tjelesne sposobnosti, mjereno testom srčano- plućnog opterećenja (CPET test) u ispitanika koji su s obzirom na stupanj razvoja bili sposobni izvesti taj test (n = 115).
The primary objective of the study was to assess the efficacy of 16 weeks of chronic treatment with oral sildenafil in paediatric subjects to improve exercise capacity as measured by the Cardiopulmonary Exercise Test (CPET) in subjects who were developmentally able to perform the test, n = 115).
Primarni cilj istraživanja bio je procijeniti djelotvornost 16-tjednog kroničnog peroralnog liječenja sildenafilom u pedijatrijskih ispitanika na poboljšanje tjelesne sposobnosti, mjereno testom srčano- plućnog opterećenja (CPET test) u ispitanika koji su s obzirom na stupanj razvoja bili sposobni izvesti taj test (n = 115).
The primary objective of the study was to compare the CCyR at 1 year in patients with newly diagnosed Ph+ CP CML who received bosutinib compared with those who received imatinib.
Primarni cilj ispitivanja bilo je uspoređivanje CCyR-a nakon jedne godine u bolesnika s novodijagnosticiranim Ph+ CP KML-om koji su dobivali bosutinib u usporedbi s pacijentima koji su dobivali imatinib.
The primary objective of the study was to compare the effects of tolvaptan + SC with placebo + SC on the time to all-cause mortality and on the time to first occurrence of cardiovascular (CV) mortality or hospitalisation for HF.
Primarni cilj ispitivanja bilo je usporediti učinke tolvaptana + SNJ sa placebom +SNJ na vrijeme do smrtnosti od bilo kojeg uzroka i na vrijeme do prve pojave kardiovaskularne (KV) smrtnosti ili hospitalizacije zbog zatajenja srca.
The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS) and the principle secondary endpoint is overall survival (OS).
Primarna mjera ishoda ispitivanja bila je procijeniti i usporediti dvije terapijske grane spram preživljenja bez progresije bolesti (PFS od engl. progression free survival) a glavna sekundarna mjera ishoda je sveukupno preživljenje (OS od engl. overall survival).
The primary objective of the trial was progression-free survival (PFS assessed by independent radiological review); the secondary endpoints included overall survival (OS), overall response rate and duration of response.
Primarni cilj ovog ispitivanja bilo je vrijeme bez progresije bolesti (PFS ocijenjeno od strane neovisnog radiološkog pregleda); sekundarne mjere ishoda uključivale su sveukupno preživljenje (OS), sveukupnu stopu odgovora i trajanje odgovora.
The primary objective of these studies was to determine if dabigatran etexilate was non-inferior to warfarin in reducing the occurrence of the primary endpoint which was the composite of recurrent symptomatic DVT and/or PE and related deaths within the 6 month treatment period.
Primarni cilj ovih ispitivanja bio je odrediti je li dabigatraneteksilat neinferioran varfarinu u smanjenju pojavnosti primarnog cilja koji je predstavljao zbroj rekurentnog simptomatskog DVT-a i/ili PE-a i povezanih smrti unutar razdoblja liječenja u trajanju od 6 mjeseci.
The primary objective of this study was to rule out a greater than 10 msec effect (i.e., to demonstrate lack of effect) of a single 80 mg oral dose of vardenafil on QTc interval compared to placebo, as measured by the change in Fridericia's correction formula (QTcF=QT/RR1/3) from baseline at the 1 hour post-dose time point.
Primarni cilj ovog ispitivanja bio je isključiti učinak veći od 10 ms (tj., pokazati nedostatak učinka) jednokratne oralne doze vardenafila od 80 mg na QTc (korigirani QT) interval u usporedbi s placebom, što se mjerilo promjenom QTc intervala korigiranog prema Fridericijinoj formuli (QTcF=QT/RR1/3) od početne vrijednosti do vremenske točke 1 sata nakon primjene doze.
The primary objective was not met.
Primarni cilj nije postignut.
The primary objective was to compare PFS in patients receiving sunitinib versus patients receiving placebo.
Primarni cilj bio je usporediti preživljenje bez progresije bolesti (PFS) u bolesnika koji su dobivali sunitinib naspram bolesnika koji su primali placebo.
The primary objective was to compare progression-free survival (PFS) in patients receiving cabozantinib versus patients receiving placebo.
Primarni cilj ispitivanja bio je uporediti preživljenje bez progresije bolesti (PFS) u bolesnika koji primaju kabozantinib s bolesnicima koji primaju placebo.
The primary objective was to demonstrate the noninferiority of T12(b.i.d.)/PR over T12(q8h)/PR.
Primarni cilj bio je pokazati neinferiornosti T12(b.i.d.)/PR u odnosu na T12(q8h)/PR.
The primary outcome assessment was the reduction in “off” time
Ocjena primarnog ishoda bila je skraćivanje off razdoblja (u satima).
The primary outcome assessment was the reduction in “off” time (hours).
Ocjena primarnog ishoda bila je skraćivanje off razdoblja (u satima).
The primary outcome measure was achievement of complete remission at 6 months defined as a Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG) of 0, and off glucocorticoid therapy.
Primarna mjera ishoda bilo je postizanje potpune remisije nakon 6 mjeseci, definirano kao BVAS/WG indeks 0 (Birmingham Vasculitis Activity Score za Wegenerovu granulomatozu) i bez primjene glukokortikoida.
The primary outcome was the mean change in disease activity in abatacept- treated patients compared to placebo-treated patients at 6 months with a subsequent double-blind assessment of safety and efficacy of abatacept and infliximab at 12 months.
Primarna mjera ishoda je bila prosječna vrijednost promjene aktivnosti bolesti u bolesnika liječenih abataceptom u usporedbi s bolesnicima koji su primali placebo nakon 6 mjeseci, s naknadnom dvostruko slijepom ocjenom sigurnosti i djelotvornosti abatacepta i infliksimaba nakon 12 mjeseci.
The primary outcome was the mean change in disease activity in abatacept- treated patients compared to placebo-treated patients at 6 months with a subsequent double-blind assessment of safety and efficacy of abatacept and infliximab at 12 months.
Primarna mjera ishoda je bila prosječna vrijednost promjene bolesti u bolesnika liječenih abataceptom u usporedbi s bolesnicima koji su primali placebo nakon 6 mjeseci, s naknadnom dvostruko slijepom ocjenom sigurnosti i djelotvornosti abatacepta i infliksimaba nakon 12 mjeseci.
The primary outcome, of the combined efficacy endpoints of death or BPD at 36 weeks GA, was not significantly different between groups, even with adjustment for gestational age as a covariate (p = 0.40), or with birth weight as a covariate (p = 0.41).
Primarni ishod, kombinirani rezultati djelotvornosti s obzirom na broj smrtnih slučajeva ili bronhopulmonalnu bolest (BPD) u gestacijskoj dobi od 36 tjedana, nije se značajno razlikovao u obje skupine, čak i uz prilagođavanje gestacijske dobi (p = 0,40) ili težine pri porodu (p = 0,41) kao kovarijable.
The primary parameter, change in body weight from baseline (time of randomisation), was assessed for body weight over time (Table 1) and the percentage of subjects who lost 5% or 10% of body weight (Table 2).
Primarni pokazatelj tj. promjena tjelesne težine u odnosu na početnu (u vrijeme randomizacije), procijenjivao se kao promjena tjelesne težine tijekom vremena i kao postotak ispitanika čija se tjelesna težina smanjila za ≥5 % ili za ≥10 % (tablica 2).
The primary parameter, change in body weight from baseline (time of randomisation), was assessed for body weight over time (Table 1) and the percentage of subjects who lost 5% or 10% of body weight (Table 2).
Primarni pokazatelj tj. promjena tjelesne težine u odnosu na početnu (u vrijeme randomizacije), procjenjivao se kao promjena tjelesne težine tijekom vremena i kao postotak ispitanika čija se tjelesna težina smanjila za ≥5 % ili za ≥10 % (tablica 2).
The primary pathway involves a cytosolic NADP+-linked enzyme, GHB dehydrogenase, that catalyses the conversion of sodium oxybate to succinic semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic semialdehyde dehydrogenase.
Primarni metabolički put uključuje citoplazmatski enzim povezan s NADP+, GHB- dehidrogenazu koja katalizira pretvaranje natrijeva oksibata u sukcinat-semialdehid koji se zatim pretvara dalje u sukcinatnu kiselinu enzimom sukcinat-semialdehid-dehidrogenaza.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66 % of the dose excreted in the urine.
Glavni putevi metabolizma u čovjeka odvijaju se pomoću alkohol dehidrogenaze i glukuronidacije te se pri tome stvaraju 5’-karboksilna kiselina i 5’-glukuronid koji čine oko 66 % doze koja se izlučuju u urinu.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66% of the administered dose.
Glavni metabolički putovi u čovjeka odvijaju se posredstvom alkohol dehidrogenaze i glukuronidacijom, pri čemu nastaju 5’-karboksilna kiselina i 5’-glukuronid, koji čine oko 66% primijenjene doze.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66% of the administered dose.
Glavni put metabolizma u čovjeka odvija se pomoću alkohol dehidrogenaze i glukuronidacije, te se pri tome stvara 5’-karboksilna kiselina i 5’-glukuronid koji čine oko 66% primijenjene doze.
The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5’-carboxylic acid and 5’-glucuronide which account for about 66% of the administered dose.
Glavni putevi metabolizma u čovjeka odvijaju se pomoću alkohol dehidrogenaze i glukuronidacije te se pri tome stvaraju 5’-karboksilna kiselina i 5’-glukuronid, koji čine oko 66% primijenjene doze.
The primary pre-specified endpoint i.e. the change from baseline in FEV1 (ml) in the modified ITT (mITT) population (n=269 and 297 in studies DPM-CF-301 and DPM-CF-302, respectively) compared to control over the 26 weeks period is provided in Table 1 alongside FEV1 presented as absolute and relative change % predicted.
Primarni prethodno specificirani ishod tj. promjena FEV1 (ml) u odnosu na početnu vrijednost u modificirane ITT (mITT) populacije (n = 269 i 297 u ispitivanjima DPM-CF-301 i DPM-CF-302) uspoređena s kontrolom tijekom razdoblja od 26 tjedana prikazana je u tablici 1, zajedno s vrijednosti FEV1 prikazanoj u obliku apsolutne i relativne promjene procijenjenog postotka (%).